Larithro (Clarithromycin)

Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This blocks the translocation step of peptide chain elongation, producing a bacteriostatic effect against a broad range of Gram‑positive, Gram‑negative, and atypical organisms without affecting human ribosomes.

The specific dose and infusion rate of Larithro are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines. Healthcare professionals should follow the product label and institutional protocols.

The pregnancy category for clarithromycin IV is not definitively established. Use during pregnancy or lactation should only occur if the potential benefit justifies the potential risk to the fetus or infant, and after careful evaluation by the treating physician.

To order Larithro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Larithro (clarithromycin) offers a broader spectrum against atypical pathogens compared with erythromycin and has a more convenient dosing schedule than some older macrolides. It also provides a stable intravenous formulation for severe infections, whereas many macrolides are only available orally.

Larithro should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Larithro is given by intravenous infusion under aseptic conditions. The infusion rate and duration are set by the prescribing clinician, typically over 30 minutes to 1 hour, and the medication is administered through a suitable IV line with appropriate monitoring.

Serious risks include hepatic dysfunction, QT‑interval prolongation leading to potentially fatal arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Larithro should be avoided in patients with known hypersensitivity to clarithromycin or other macrolides, those with a history of significant QT prolongation, and individuals taking contraindicated medications that may cause dangerous drug interactions. Caution is also advised in severe hepatic impairment.